{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:54:32Z","timestamp":1781754872209,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01806-x","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:49:34Z","timestamp":1780663774000},"page":"3331-3344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"1806_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, et\u00a0al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"issue":"2","key":"1806_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et\u00a0al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1806_CR3","doi-asserted-by":"crossref","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et\u00a0al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl. 1 to No. 1):1\u201378.","DOI":"10.23736\/S2784-8671.21.07132-2"},{"issue":"11","key":"1806_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et\u00a0al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1806_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et\u00a0al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res"},{"key":"1806_CR6","doi-asserted-by":"crossref","unstructured":"Strober B, ryan C, van de Kerkhof P, van der Walt J, Kimball aB, Barker J, et\u00a0al.; International Psoriasis Council Board members and Councilors. recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J am acad Dermatol 2020;82:117\u201322.","DOI":"10.1016\/j.jaad.2019.08.026"},{"issue":"11","key":"1806_CR7","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1007\/s12325-022-02305-z","volume":"39","author":"MA Richard","year":"2022","unstructured":"Richard MA, Aubin F, Beneton N, et\u00a0al. Moderate psoriasis in clinical practice: French expert consensus using a modified Delphi method. Adv Ther. 2022;39(11):5203\u201315.","journal-title":"Adv Ther"},{"issue":"4","key":"1806_CR8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008\u201315.","journal-title":"J Adv Nurs"},{"issue":"4","key":"1806_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, et\u00a0al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.002.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1806_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et\u00a0al. Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus. Dermatol Ther (Heidelb). 2024;14(4):919\u201332. https:\/\/doi.org\/10.1007\/s13555-024-01135-x.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1806_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jdv.16966","volume":"35","author":"NM Golbari","year":"2021","unstructured":"Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2021;35(2):417\u201321. https:\/\/doi.org\/10.1111\/jdv.16966.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1806_CR12","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13555-025-01474-3","volume":"15","author":"B Strober","year":"2025","unstructured":"Strober B, Patel M, Kaldas MI, et\u00a0al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification. Dermatol Ther (Heidelb). 2025;15(9):2409\u201321. https:\/\/doi.org\/10.1007\/s13555-025-01474-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1806_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","volume":"29","author":"G Carretero","year":"2018","unstructured":"Carretero G, Puig L, Carrascosa JM, et\u00a0al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018;29(4):334\u201346. https:\/\/doi.org\/10.1080\/09546634.2017.1395794.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1806_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13555-023-01065-0","volume":"14","author":"ME Horner","year":"2024","unstructured":"Horner ME, Orroth KK, Ma J, Duan Y, Cordey M. Redefining disease severity with special area involvement and reflecting on treatment patterns in a real-world psoriasis population. Dermatol Ther (Heidelb). 2024;14(1):187\u201399. https:\/\/doi.org\/10.1007\/s13555-023-01065-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1806_CR15","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s13555-025-01466-3","volume":"15","author":"A Armstrong","year":"2025","unstructured":"Armstrong A, Strober B, Gisondi P, et\u00a0al. Benefits of earlier apremilast initiation in patients with psoriasis and limited skin involvement: results from a real-world retrospective study. Dermatol Ther (Heidelb). 2025;15(10):2911\u201323. https:\/\/doi.org\/10.1007\/s13555-025-01466-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1806_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2025.1625","volume":"161","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Gondo GC, Merola JF, et\u00a0al. Defining on-treatment remission in plaque psoriasis: a consensus statement from the National Psoriasis Foundation. JAMA Dermatol. 2025;161(8):863\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2025.1625.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1806_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2026.2626219","volume":"37","author":"A Costanzo","year":"2026","unstructured":"Costanzo A, Bardazzi F, Burlando M, et\u00a0al. Toward the definition of moderate psoriasis: an expert opinion. J Dermatolog Treat. 2026;37(1):2626219. https:\/\/doi.org\/10.1080\/09546634.2026.2626219.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01806-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:24:16Z","timestamp":1781753056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01806-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luigi Gargiulo has been a consultant and\/or speaker and has served as an advisory board member for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Galderma, Johnson and Johnson, Incyte, LEO Pharma, Novartis, Pierre Fabre, Pfizer,\u00a0Sanofi, and UCB Pharma. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Angelo V. Marzano has conflict of interest with AbbVie, Boehringer Ingelheim, Bristol Myers, Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi and UCB. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma, and Almirall. Anna Balato has received honoraria for participation in advisory boards, meetings, or as a speaker for AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, Sanofi-Genzyme, and UCB Pharma. Federico Bardazzi has been a consultant adviser and clinical study investigator for Eli Lilly, AbbVie, Novartis, Leo Pharma, Sandoz, Bristol Myers, Abiogen-Pharma, Celgene, and Janssen. Martina Burlando has acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, and UCB Pharma. Carlo G. Carrera has served as a board participant or speaker for AbbVie, Eli Lilly, Janssen, Novartis, Celgene, Almirall, and Leo Pharma. Andrea Carugno has been a consultant and\/or speaker for AbbVie, Leo Pharma, Eli Lilly, Novartis, Janssen-Cilag, Amgen, Almirall, UCB Pharma, and Boehringer Ingelheim. Paolo Dapavo has been a speaker for Novartis, AbbVie, Sanofi, UCB, Janssen, Eli Lilly, and Leo Pharma. Anna Campanati has served as a speaker, consultant, or advisory board member for Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte, Leo Pharma, Merck Sharp & Dohme, Janssen-Cilag, Novartis, Pfizer, Regeneron, Sanofi-Aventis, and UCB Pharma. Claudio Guarneri has been a scientific consultant, speaker, and clinical study investigator for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Almirall, and Leo Pharma. Emanuele Trovato is involved in an intermittent project focused on consulting and\/or advisory relationships and\/or travel-congress support with Eli Lilly, Novartis, Janssen-Cilag, AbbVie, and Almirall. Marina Venturini served as a speaker or advisory board member for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. Francesco Loconsole served on advisory boards and\/or received honoraria for lectures from Abbvie, Janssen-Cilag, Novartis, Lilly, Sanofi. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, Janssen, Leo Pharma, and Novartis. Diego Orsini has been a speaker and\/or consultant for AbbVie, Leo Pharma, UCB, Bristol-Myers Squibb, and Boehringer Ingelheim. Simone Ribero has served as an advisory board member and\/or consultant and has received fees and speaker\u2019s honoraria or has participated in clinical studies for AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, and Sanofi Genzyme.\u00a0Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Giampiero Girolomoni, Giovanni Pappagallo, Stefano Piaserico, Andrea Conti, Valentina Dini and Nicoletta Bernardini have nothing to disclose. Anna Campanati and Diego Orsini are Editorial Board members of Dermatology and Therapy. Anna Campanati and Diego Orsini were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board approval was exempted for this study as its procedures did not include human subjects and did not deviate from good clinical practice. All the involved dermatologists gave their approval for the study to be published. All the dermatologists who were part of the consensus were involved in the writing and\/or revision of the manuscript. All the dermatologists who participated in the consensus were aware of the objective of the study, and they all knew that the manuscript would be published. The participants gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}